ERBB2 and neoplasm: The mucin on tumor cell surface could inhibit the interaction between trastuzumab and its target epitope on the extracellular domain of the HER2 protein, while it would not affect the interaction of the HER2 immunostaining antibody and the intracellular domain of HER2.